Muscle disease drug developer Avidity, which counts Eli Lilly, EMS, Takeda and ST Pharm as investors, went public in a significantly upized IPO.

Avidity Biosciences, a US-based muscle disease drug developer backed by pharmaceutical firms Eli Lilly, EMS, ST Pharm and Takeda, floated on the Nasdaq Global Market on Friday in a $259m initial public offering. The offering came after a considerable hike in its size, Avidity having increased the number of shares from 10 million to 14.4…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.